by | Jan 5, 2024 | Uncategorized
Healio spoke with Chakra Chaulagain, MD, about a retrospective observational study on prescribing patterns and outcomes of bortezomib in newly diagnosed patients with multiple myeloma presented at ASH Annual Meeting and Exposition.The study included 2,522 patients...
by | Dec 29, 2023 | Uncategorized
Healio spoke with Chakra Chaulagain, MD, about phase 3 PERSEUS trial results presented at ASH 2023.Findings from the randomized trial showed that among patients with newly diagnosed multiple myeloma, daratumumab (Darzalex, Janssen) combined with bortezomib (Velcade,...
by | Dec 19, 2023 | Uncategorized
SAN DIEGO — All 38 patients with heavily pretreated multiple myeloma responded to an investigational chimeric antigen receptor T-cell therapy, results of a phase 1 study presented at ASH Annual Meeting and Exhibition showed.The CAR-T product, now known as...
by | Dec 19, 2023 | Uncategorized
Source: CureToday articles A treatment combination of Sarclisa, Kyprolis, Revlimid and dexamethasone demonstrated a complete response in patients who were newly diagnosed with multiple myeloma. Read More
by | Dec 14, 2023 | Uncategorized
Improving representation of African American patients in multiple myeloma research is essential to preventing outcome disparities in this population, according to a spotlight session at ASH Annual Meeting and Exposition.“The incidence of multiple myeloma in African...
by | Dec 13, 2023 | Uncategorized
Daratumumab combined with bortezomib, lenalidomide and dexamethasone outperformed bortezomib, lenalidomide and dexamethasone alone in patients with newly diagnosed multiple myeloma, according to results of the phase 3 PERSEUS trial.The findings — presented at ASH...
